文献速递心力衰竭与心肌病血脂与心血管预防

罕见肥厚型心肌病遗传变异在中年人群中的表型表达与结局

Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

该研究基于英国生物银行200,584名参与者的全外显子测序和部分心脏磁共振数据,发现肥厚型心肌病相关肌节基因的致病/可能致病变异(SARC-HCM-P/LP)患病率为0.25%(1/407)。这些变异与死亡或主要不良心脏事件风险增加相关(HR 1.69),主要由心力衰竭驱动(HR 4.23),但仅18.4%携带者出现明显肥厚。

要点

  • SARC-HCM-P/LP变异在中年人群中患病率低(0.25%),外显率低。
  • 携带者死亡或主要不良心脏事件风险增加(HR 1.69),心衰风险显著升高(HR 4.23)。
  • 调整室壁厚度后,变异仍与心衰相关(HR 6.74),提示独立风险。

核心结论

  • SARC-HCM-P/LP变异在中年人群中总体外显率低,但增加不良心血管结局风险,且心肌病变表型较轻。
  • 尽管绝对事件率低,识别这些变异可能有助于超越家族性疾病的风险分层。

研究设计与样本

  • 研究分析英国生物银行参与者的全外显子测序和心脏磁共振成像,按肌节编码基因变异状态分层。
  • 共纳入200,584名参与者进行变异分析,其中21,322名同时有心脏磁共振和全外显子测序数据。

主要发现

  • HCM相关肌节基因罕见变异(等位基因频率<0.00004)总体患病率为2.9%(n=5,712;1/35),SARC-HCM-P/LP变异患病率为0.25%(n=493;1/407)。
  • SARC-HCM-P/LP变异与死亡或主要不良心脏事件风险增加相关(HR 1.69;95%CI 1.38-2.07;P<0.001),主要由心力衰竭驱动(HR 4.23;95%CI 3.07-5.83;P<0.001)。
  • 在21,322名参与者中,SARC-HCM-P/LP变异与左室最大壁厚不对称增加相关(10.9±2.7 mm vs 9.4±1.6 mm;P<0.001),但仅18.4%(n=9/49;95%CI 9%-32%)出现肥厚(≥13 mm)。
  • 调整壁厚后,SARC-HCM-P/LP变异仍与心力衰竭相关(HR 6.74;95%CI 2.43-18.7;P<0.001)。

临床怎么用

  • 在中年人群中识别SARC-HCM-P/LP变异可能提示心衰风险增加,即使无明显心肌肥厚。
  • 对携带者应考虑加强心血管风险监测和随访,尤其是心力衰竭的早期识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is caused by rare variants in sarcomere-encoding genes, but little is known about the clinical significance of these variants in the general population. OBJECTIVES: The goal of this study was to compare lifetime outcomes and cardiovascular phenotypes according to the presence of rare variants in sarcomere-encoding genes among middle-aged adults. METHODS: This study analyzed whole exome sequencing and cardiac magnetic resonance imaging in UK Biobank participants stratified according to sarcomere-encoding variant status. RESULTS: The prevalence of rare variants (allele frequency <0.00004) in HCM-associated sarcomere-encoding genes in 200,584 participants was 2.9% (n = 5,712; 1 in 35), and the prevalence of variants pathogenic or likely pathogenic for HCM (SARC-HCM-P/LP) was 0.25% (n = 493; 1 in 407). SARC-HCM-P/LP variants were associated with an increased risk of death or major adverse cardiac events compared with controls (hazard ratio: 1.69; 95% confidence interval [CI]: 1.38-2.07; P < 0.001), mainly due to heart failure endpoints (hazard ratio: 4.23; 95% CI: 3.07-5.83; P < 0.001). In 21,322 participants with both cardiac magnetic resonance imaging and whole exome sequencing, SARC-HCM-P/LP variants were associated with an asymmetric increase in left ventricular maximum wall thickness (10.9 ± 2.7 mm vs 9.4 ± 1.6 mm; P < 0.001), but hypertrophy (≥13 mm) was only present in 18.4% (n = 9 of 49; 95% CI: 9%-32%). SARC-HCM-P/LP variants were still associated with heart failure after adjustment for wall thickness (hazard ratio: 6.74; 95% CI: 2.43-18.7; P < 0.001). CONCLUSIONS: In this population of middle-aged adults, SARC-HCM-P/LP variants have low aggregate penetrance for overt HCM but are associated with an increased risk of adverse cardiovascular outcomes and an attenuated cardiomyopathic phenotype. Although absolute event rates are low, identification of these variants may enhance risk stratification beyond familial disease.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. de Marvao A, McGurk KA, Zheng SL, et al. Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021. PMID: 34503678. doi:10.1016/j.jacc.2021.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。